Actively Recruiting

Age: 18Years +
All Genders
NCT06043193

Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.

Led by Hospices Civils de Lyon · Updated on 2025-06-11

100

Participants Needed

4

Research Sites

134 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study consists of having participants complete quality of life questionnaires (PROMs) at the time of the cures +/- one week and in the middle of the intercure time +/- one week. As all the collection times do not correspond to a consultation or a visit to a medical service, The investigator wanted to develop a remote, computerized data collection solution. Researchers have programmed an AURA-RIV-TNE care pathway (MOCAs: Engine for the organization and coordination of health acts) on the myHCL patient environment, taking up the course of the study presented in the form of a table in paragraph 6.2. Once the patient consents to participate in the study, he must create an account on the patient interface of his investigation center (myHCL, myCHUGA etc) as much as possible to facilitate data extraction. Once the patient consents to participate in the study, the MOCAs AURA-RIV-TNE course will be associated with him in the Easily software, by defining the date week 0 (baseline) of the first treatment. This will allow automated sending of MAIL and SMS reminders at each questionnaire time. The MAILs will contain an internet link allowing the participant to be directly written to the questionnaires to be completed. A reminder system will be possible if the patient does not complete the questionnaire.

CONDITIONS

Official Title

Evaluation of the Quality of Life and Tolerance of Patients Treated With Vectorized Internal Radiotherapy (RIV) for a Neuro Endocrine Tumor (NET) in the Auvergne-Rhône-Alpes Region.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age >18 years;
  • Patient starting treatment with RIV validated in the RENATEN RCP;
  • Patient having received written information about the study;
  • Collection of the patient's non-objection
  • Patients for whom treatment with RIV is administered within the framework of a clinical trial, may be included in the AURARIV-TNE study according to the written indications written in the 2 nd protocol of the sponsor of the clinical trial;
  • Patients undergoing re-treatment with RIV can be included;
Not Eligible

You will not qualify if you...

  • Persons deprived of their liberty by a judicial or administrative decision;
  • Adults subject to a legal protection measure (guardianship, curatorship);

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

CHU de Saint-Etienne, Hôpital Nord

Saint-Priest-en-Jarez, Saint-Etienne, France, 42270

Actively Recruiting

2

CH Métropole Savoie

Chambéry, France, 73000

Actively Recruiting

3

Centre de Lutte Contre le Cancer Jean Perrin

Clermont-Ferrand, France, 63011

Actively Recruiting

4

Hospices Civils de Lyon, Hopital Lyon Sud

Lyon, France, 69495

Actively Recruiting

Loading map...

Research Team

N

Nicolas JACQUET-FRANCILLON, MD

CONTACT

A

Adeline MANSUY

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here